ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors

Bart Lutterbach(Vanderbilt University), Jennifer J. Westendorf(Vanderbilt University), Bryan Linggi(Vanderbilt University), Andrea K. Patten(Laboratoire de Biochimie), Mariko Moniwa(University of Manitoba), James Davie(University of Manitoba), Khanh D. Huynh(Institute of Molecular Biology and Biophysics), Vivian J. Bardwell(Institute of Molecular Biology and Biophysics), Robert M. Lavinsky(Howard Hughes Medical Institute), Michael G. Rosenfeld(Howard Hughes Medical Institute), Christopher K. Glass(University of California, San Diego), Edward Seto(Moffitt Cancer Center), Scott W. Hiebert(Vanderbilt University)
Molecular and Cellular Biology
December 1, 1998
Cited by 439Open Access
Full Text

Abstract

t(8;21) is one of the most frequent translocations associated with acute myeloid leukemia. It produces a chimeric protein, acute myeloid leukemia-1 (AML-1)-eight-twenty-one (ETO), that contains the amino-terminal DNA binding domain of the AML-1 transcriptional regulator fused to nearly all of ETO. Here we demonstrate that ETO interacts with the nuclear receptor corepressor N-CoR, the mSin3 corepressors, and histone deacetylases. Endogenous ETO also cosediments on sucrose gradients with mSin3A, N-CoR, and histone deacetylases, suggesting that it is a component of one or more corepressor complexes. Deletion mutagenesis indicates that ETO interacts with mSin3A independently of its association with N-CoR. Single amino acid mutations that impair the ability of ETO to interact with the central portion of N-CoR affect the ability of the t(8;21) fusion protein to repress transcription. Finally, AML-1/ETO associates with histone deacetylase activity and a histone deacetylase inhibitor impairs the ability of the fusion protein to repress transcription. Thus, t(8;21) fuses a component of a corepressor complex to AML-1 to repress transcription.


Related Papers

No related papers found

Powered by citation graph analysis